Back to Search
Start Over
Recognition and management of significant drug interactions in HIV patients: challenges in using available data to guide therapy.
- Source :
-
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2010 Nov; Vol. 88 (5), pp. 712-9. Date of Electronic Publication: 2010 Jul 28. - Publication Year :
- 2010
-
Abstract
- Combination antiretroviral therapy (cART) has improved survival rates in HIV-infected patients; however, patients now experience comorbidities that require pharmacological intervention, thereby increasing the risk of drug-drug interactions (DDIs). HIV protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and the CCR5 antagonist maraviroc are primarily metabolized via the cytochrome P450 (CYP) system and are prone to pharmacokinetic interactions.(1,2) This article addresses some key challenges that prescribers face when using available drug interaction-data resources in making day-to-day clinical decisions.
- Subjects :
- Antiviral Agents pharmacokinetics
Clinical Competence
Drug Labeling
Drug Therapy, Combination
Humans
Information Dissemination
Practice Guidelines as Topic
Practice Patterns, Physicians'
Risk Assessment
Risk Factors
Treatment Outcome
Adverse Drug Reaction Reporting Systems
Antiviral Agents adverse effects
Drug Interactions
HIV Infections drug therapy
Medication Errors prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 1532-6535
- Volume :
- 88
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Clinical pharmacology and therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 20668439
- Full Text :
- https://doi.org/10.1038/clpt.2010.130